JO3027B1 - نيوكليوسيدات يوراسيل سبيرواوكسيتان - Google Patents

نيوكليوسيدات يوراسيل سبيرواوكسيتان

Info

Publication number
JO3027B1
JO3027B1 JOP/2010/0138A JOP20100138A JO3027B1 JO 3027 B1 JO3027 B1 JO 3027B1 JO P20100138 A JOP20100138 A JO P20100138A JO 3027 B1 JO3027 B1 JO 3027B1
Authority
JO
Jordan
Prior art keywords
phenyl
optionally substituted
c6alkyl
compounds
spirooxetane nucleosides
Prior art date
Application number
JOP/2010/0138A
Other languages
English (en)
Inventor
Vandyck Koen
Jean-Marie Pierre Raboisson Bernard
Abdellah Tahri
Koen Vandyck
Hu Lili
Hugo Tim Jonckers Maria
Original Assignee
Janssen Products Lp
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Products Lp, Medivir Ab filed Critical Janssen Products Lp
Application granted granted Critical
Publication of JO3027B1 publication Critical patent/JO3027B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

مركبات لها الصيغة I: بما فيها أية مشابهات هندسية حيث : R4 هي احادي فوسفات, ثنائي فوسفات أو ثلاثي فوسفات استر, أو R4 هي أو R7 هي فينيل مستبدلة اختيارياً أو نافثيل مستبدل اختيارياً, أو اندوليل مستبدل اختيارياً. R8 و R8' هما هيدروجين, الكيل ك1 – ك6 , بنزيل, أوفينيل أو R8 و R8' تشكلان الكيل حلقي ك3-ك7 R9 هي الكيل ك1- ك10, الكيل حلقي ك3- ك7, فينيل أو فينيل الكيل ك1- ك6, حيث يكون شق الفينيل في الفينيل أو الكيل ك1- ك6 فينيل مستبدل اختيارياً, أو ملحها أو تميؤها المقبول دوائياً, أو صيغها الدوائية واستعمال المركبات I بصفة مثبطات لفيروس سي الالتهاب الكبدي.
JOP/2010/0138A 2009-05-14 2010-05-04 نيوكليوسيدات يوراسيل سبيرواوكسيتان JO3027B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09160215 2009-05-14

Publications (1)

Publication Number Publication Date
JO3027B1 true JO3027B1 (ar) 2016-09-05

Family

ID=40823307

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0138A JO3027B1 (ar) 2009-05-14 2010-05-04 نيوكليوسيدات يوراسيل سبيرواوكسيتان

Country Status (38)

Country Link
US (2) US8481510B2 (ar)
EP (2) EP2430035B1 (ar)
JP (2) JP5778135B2 (ar)
KR (1) KR101806837B1 (ar)
CN (1) CN102439024B (ar)
AP (1) AP2783A (ar)
AR (1) AR076579A1 (ar)
AU (1) AU2010247439B2 (ar)
BR (1) BRPI1010579A2 (ar)
CA (1) CA2760329C (ar)
CL (1) CL2011002859A1 (ar)
CO (1) CO6440533A2 (ar)
CR (1) CR20120297A (ar)
CY (2) CY1114081T1 (ar)
DK (2) DK2511282T3 (ar)
EA (1) EA022084B1 (ar)
EC (1) ECSP11011461A (ar)
ES (2) ES2477598T3 (ar)
HN (1) HN2011003014A (ar)
HR (2) HRP20130554T1 (ar)
IL (1) IL215955A (ar)
JO (1) JO3027B1 (ar)
ME (1) ME01478B (ar)
MX (1) MX2011012027A (ar)
MY (1) MY157018A (ar)
NI (1) NI201100197A (ar)
NZ (1) NZ596073A (ar)
PL (2) PL2430035T3 (ar)
PT (2) PT2511282E (ar)
RS (1) RS52822B (ar)
SG (1) SG175981A1 (ar)
SI (2) SI2511282T1 (ar)
SM (2) SMT201300078B (ar)
TW (1) TWI461432B (ar)
UA (1) UA105790C2 (ar)
UY (1) UY32642A (ar)
WO (1) WO2010130726A1 (ar)
ZA (1) ZA201108309B (ar)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
US9012428B2 (en) 2010-11-10 2015-04-21 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
US9006209B2 (en) 2010-11-10 2015-04-14 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
AU2015252113B2 (en) * 2010-11-30 2017-05-04 Gilead Pharmasset Llc Compounds
PT3042910T (pt) * 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
WO2012142523A2 (en) * 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
KR101857337B1 (ko) * 2013-03-08 2018-05-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 신규한 뉴클레오시드 포스포라미데이트 화합물 및 이의 용도
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
WO2014194826A1 (zh) * 2013-06-06 2014-12-11 南京圣和药业有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
EP3074412A4 (en) * 2013-11-28 2017-05-31 Janssen Sciences Ireland UC Crystal form of nucleoside inhibitor of hcv
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4135716A1 (en) * 2020-04-14 2023-02-22 Janssen Pharmaceuticals, Inc. Spirocyclic nucleoside analogues for the treatment of hepatitis e
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3487A1 (fr) * 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
JP5080973B2 (ja) * 2004-06-24 2012-11-21 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルスの感染を処置するためのヌクレオシドアリールホスホルアミダート
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
JP2009526850A (ja) * 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان

Also Published As

Publication number Publication date
BRPI1010579A2 (pt) 2016-03-15
ME01478B (me) 2014-04-20
EP2430035B1 (en) 2013-04-03
KR101806837B1 (ko) 2017-12-08
EA201171406A1 (ru) 2012-05-30
WO2010130726A1 (en) 2010-11-18
TW201100442A (en) 2011-01-01
CY1114081T1 (el) 2016-07-27
EP2511282A1 (en) 2012-10-17
ECSP11011461A (es) 2012-02-29
NZ596073A (en) 2013-02-22
US20130217648A1 (en) 2013-08-22
SMT201300078B (it) 2013-09-06
AP2011005958A0 (en) 2011-10-31
PT2511282E (pt) 2014-07-11
SG175981A1 (en) 2011-12-29
HK1166326A1 (en) 2012-10-26
AP2783A (en) 2013-10-31
AU2010247439B2 (en) 2014-09-25
RS52822B (sr) 2013-10-31
JP2015180692A (ja) 2015-10-15
ES2411086T3 (es) 2013-07-04
CL2011002859A1 (es) 2012-07-20
CY1115383T1 (el) 2017-01-04
DK2430035T3 (da) 2013-05-27
CN102439024B (zh) 2014-09-17
AR076579A1 (es) 2011-06-22
UA105790C2 (uk) 2014-06-25
PL2430035T3 (pl) 2013-08-30
UY32642A (es) 2010-11-30
IL215955A0 (en) 2012-01-31
SI2511282T1 (sl) 2014-09-30
CN102439024A (zh) 2012-05-02
MX2011012027A (es) 2012-02-28
HRP20140605T1 (hr) 2014-09-26
DK2511282T3 (da) 2014-07-07
HRP20130554T1 (xx) 2013-07-31
MY157018A (en) 2016-04-15
JP5778135B2 (ja) 2015-09-16
KR20120018355A (ko) 2012-03-02
CO6440533A2 (es) 2012-05-15
ES2477598T3 (es) 2014-07-17
US20120065156A1 (en) 2012-03-15
CR20120297A (es) 2012-10-25
ZA201108309B (en) 2013-04-24
JP2012526764A (ja) 2012-11-01
PL2511282T3 (pl) 2014-09-30
SI2430035T1 (sl) 2013-08-30
PT2430035E (pt) 2013-05-22
IL215955A (en) 2015-03-31
TWI461432B (zh) 2014-11-21
AU2010247439A1 (en) 2011-12-01
NI201100197A (es) 2012-05-28
US8481510B2 (en) 2013-07-09
CA2760329C (en) 2017-10-31
HN2011003014A (es) 2014-06-30
EA022084B1 (ru) 2015-10-30
CA2760329A1 (en) 2010-11-18
SMT201400085B (it) 2014-09-08
EP2511282B1 (en) 2014-04-02
EP2430035A1 (en) 2012-03-21
US8933052B2 (en) 2015-01-13

Similar Documents

Publication Publication Date Title
JO3027B1 (ar) نيوكليوسيدات يوراسيل سبيرواوكسيتان
UY32308A (es) Nucleótidos uracil ciclopropílicos
MX2011011136A (es) Eteres diarilicos.
PH12014501134B1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
UA111770C2 (uk) Інгібітори бромдомену
NZ603232A (en) Nucleoside phosphoramidates
NZ595280A (en) Hepatitis c virus inhibitors
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
EA201170118A1 (ru) Циклопропильные ингибиторы полимеразы
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
AR073603A1 (es) Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
TN2010000038A1 (en) Organic compounds
TW200942529A (en) Pyrrolidinyl derivatives and uses thereof
MX2013007892A (es) Derivados de fenetilsulfona isoindolina y su uso.
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
TNSN08369A1 (en) Benzimidazole derivatives